Antitope Ltd., a biotechnology company specialising in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity, has signed an research agreement with Liverpool-based, Eden Biodesign Ltd. for the development of therapeutic antibodies.
Under the terms of agreement, Antitope will apply its proprietary technologies towards the generation of a high yielding mammalian cell line for manufacture of the therapeutic.
Dr Matthew Baker, chief scientific officer and co-founder of Antitope said, "We are very pleased to work with Eden Biodesign and assist in the development of their antibody therapeutics. The partnership combines Antitope's core technologies in the generation of high-yielding manufacturing cell lines for the production of therapeutic antibodies with Eden Biodesign’s extensive experience in biopharmaceutical discovery, process development and GMP manufacturing."
Dr Crawford Brown, chief executive officer of Eden Biodesign, Ltd., a member of the Watson Group, added, “After a careful and diligent search for a partner capable of both meeting our exacting quality standards and delivering highly productive and compliant cGMP production cell lines, we are very happy to be working with Antitope on this important project.”